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c Department of Biology, Stanford University, Stanford, CaliforniaObjective: To determine the effect of maternal age on the average number of euploid embryos retrieved during oocyte harvest as part of
an in vitro fertilization (IVF) cycle, including the probability of retrieving at least one euploid embryo in a cohort (PrE).
Design: Retrospective study.
Setting: Preimplantation genetic screening (PGS) laboratory.
Patient(s): Women aged 18 to 48 years undergoing IVF treatment.
Intervention(s): Use of 24-chromosome single-nucleotide polymorphism (SNP)-based PGS of day-3 and day-5 embryo biopsies.
Main OutcomeMeasure(s): Relationships between maternal age and the rate of embryos that tested as euploid (hereafter referred to as
‘‘euploid embryos’’), the average number and proportion of euploid embryos per IVF cycle, and PrE.
Result(s): We analyzed 22,599 day-3 embryos and 15,112 day-5 embryos. In women aged 27 to 35 years, the median proportion of
euploid embryos in each cycle remained constant at 35% in day-3 biopsies and 55% in day-5 biopsies, but it decreased rapidly
after age 35. On average, women in their late 20s had four euploid embryos (day 3 or day 5) per cycle, but this number decreased
linearly (R2 R 0.983) after 35 years of age. The effect of maternal age on PrE was similar, with a rapid exponential decline (R2 ¼
0.986). Across all maternal ages, the euploid proportion and number of embryos per cycle were counterbalanced, so the number of
euploid embryos per cycle was the same for day-3 and day-5 biopsies. This suggests that the loss of embryos from day 3 to day 5 was
primarily due to aneuploidy.
Conclusion(s): Our results conﬁrm the known inverse relationship between advanced maternal age (>35 years) and embryo
euploidy, demonstrating that equal numbers of euploid embryos are available at day 3 and day 5. (Fertil Steril 2016;105:Use your smartphone1307–13. 2016 The Authors. Published by Elsevier Inc. on behalf of the American Society
for Reproductive Medicine. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).)
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A bnormal chromosome number, or aneuploidy, iscommon in human embryos (1–3). It is responsiblefor more than half of all missed abortions and
miscarriages (4–6), and it is the leading cause of congenital
birth defects (2, 3, 7, 8). Embryo-wide whole chromosomal
aneuploidy results mainly from meiotic errors during
oocyte generation (2, 7–9), which become increasingly
common as women age (1, 3, 7, 10, 11). For example,
trisomies occur in nearly 35% of all clinically recognized
pregnancies in women over 40 years old, but in only 2% to
3% of all clinically recognized pregnancies in women in
their mid-20s (2).
Because of the clinical signiﬁcance of aneuploidy, it is the
primary reason people choose to use preimplantation genetic
screening (PGS), a technique that can detect aneuploidy in a
single blastomere from day-3 cleavage-stage embryos or
from a small number of trophectoderm cells from day-5 blas-
tocyst-stage embryos (10). Preimplantation genetic screening
is based on the hypothesis that selective transfer of euploid
embryos can improve clinical outcomes for patients undergo-
ing in vitro fertilization (IVF), particularly those at risk for
fetal aneuploidy or who have experienced recurrent preg-
nancy loss (12). Early efforts to realize this goal were
hampered by the use of ﬂuorescence in situ hybridization
(FISH) analysis, which identiﬁes only 25% of all chromo-
somal abnormalities (1, 13, 14) and led to disappointing
results in randomized controlled trials (15, 16). More recent
studies using array-based PGS have demonstrated major im-
provements in clinical pregnancy rates (17–20).
Despite the fact that a high percentage of embryonic cells
are aneuploid (14) and many day-3 embryos are mosaic (i.e.,
they include both euploid and aneuploid cells) (21, 22), PGS
has until recently typically been performed on day-3 biopsy
samples due to its ease and reliability. Advances in embry-
ology and cryopreservation techniques (1, 23) have,
however, improved IVF success rates for day-5 embryos. In
addition, day-5 embryos, by virtue of the attrition of aneu-
ploid cells that occurs during development, have considerably
lower frequencies of mosaicism (22) and aneuploidy (24).
As a result, PGS has shifted toward 24-chromosome
comprehensive chromosome screening of day-5 embryos,
which can help women with fertility issues, such as advanced
maternal age (>35 years old), have a successful pregnancy
(12). Two common methods of comprehensive chromosome
screening are array comparative genomic hybridization and
single-nucleotide polymorphism (SNP) arrays. Although
both of these techniques can detect chromosomal copy-
number abnormalities, SNP arrays provide additional infor-
mation about other genetic features of the embryo, such as
the parental origin of chromosomes, the mitotic/meiotic
origin of aneuploidies (11), and whether disomic chromo-
somes are uniparental (i.e., from only a single parent) (13).
Previously, we developed an informatics-based SNP array
PGS technology called Parental Support, which is as accurate
as metaphase karyotyping, the gold standard technique for
chromosome analysis (22). Parental Support uses parental
genetic information to improve thedeterminationof embryonic
chromosomal copy numbers. Importantly, this algorithm
computes the statistical conﬁdence for each copy-number
ORIGINAL ARTICLE: GENETICS1308call, which allows embryo quality to be assessed quantitatively
rather than by qualitative methods based on embryo
morphology that may not be associated with chromosome
abnormalities (25).
Between 2009 and 2014, more than 46,000 embryos were
analyzed using this SNP-based PGS test in our Clinical Labo-
ratory Improvement Amendments (CLIA)–approved labora-
tory. For both day-3 and day-5 biopsies, the number of
embryos submitted per cycle gradually decreased with
increasing maternal age, and the proportion of embryos that
tested as euploid decreased rapidly after age 35 (Fig. 1) (26).
Here, we report the number and proportion of embryos that
were determined to be euploid (hereafter referred to as euploid
embryos) per IVF cycle and the probability of retrieving at
least one euploid embryo per cohort (PrE) as functions of
maternal age. We also compare trends between day-3 and
day-5 biopsies as well as those between embryos from egg do-
nors and from women who used their own eggs (hereafter
referred to as nondonors).
MATERIALS AND METHODS
Samples
Between February 2009 and March 2014, 181 IVF centers
submitted 46,439 embryo biopsies from 6,365 IVF cycles to
Natera, Inc. (San Carlos, CA) for 24-chromosome PGS. Indica-
tions for PGS included history of aneuploid pregnancy or IVF
failure, recurrent pregnancy loss, advanced maternal age, and
gender selection. Each IVF center cultured embryos and bio-
psied cells according to their standard operating procedures
and then shipped the isolated cells overnight. Due to the retro-
spective nature of this study, Ethical & Independent Review
Services (Corte Madera, CA) exempted it from institution re-
view board approval (E&I Exemption Number 10806-05).SNP-based PGS
We performed DNA ampliﬁcation, SNP genotyping, and
copy-number determination as described elsewhere (22).
Brieﬂy, single cells were washed, lysed, and ampliﬁed using
either whole-genome ampliﬁcation or multiple displacement
ampliﬁcation. Then the ampliﬁed DNA was genotyped using
Illumina SNP microarrays.
Microarray data were processed with the Parental Sup-
port algorithm to infer copy numbers and calculate the conﬁ-
dence of each copy-number call. This algorithm takes
advantage of the genetic relationships between parental and
embryonic DNA to enhance copy-number calls made from
potentially error-prone single-cell microarray data (22). Spe-
ciﬁcally, parental genotypes and crossover frequency data are
used to calculate expected allele distributions for thousands
of heterozygous SNPs in the embryonic genome (27). At
each SNP, the likelihoods of different copy-number hypothe-
ses (e.g., ampliﬁcation or deletion) are determined, and then
the joint likelihood across all SNPs on a chromosome is calcu-
lated. The hypothesis with the maximum likelihood is called
as the chromosome copy number, and its statistical conﬁ-
dence is computed by comparing the likelihoods of all hy-
potheses. On the basis of these results for all chromosomes,
embryos were classiﬁed as euploid or aneuploid.VOL. 105 NO. 5 / MAY 2016
FIGURE 1
A B
C
Maternal age relationships in more than 18,000 day-5 preimplantation embryos tested with 24-chromosome single-nucleotide polymorphism
(SNP)-based preimplantation genetic screening (PGS). (A) The number of embryos per in vitro fertilization (IVF) cycle submitted for testing
gradually decreases as maternal age increases from 25 to 45 years old. Data points indicate the 50th percentile, and whiskers above and below
these points correspond to the 75th and 25th percentiles, respectively. Age groups with less than 45 cycles are not shown. (B) On the basis of
PGS results, embryos from both egg donors and nondonors were classiﬁed as either euploid or aneuploid. Women 24 to 35 years old have the
highest percentage of euploid embryos. Data points and whiskers show the mean and one standard deviation (SD), respectively. The logarithm
of the number of embryos in each age group is mapped onto a color gradient from red (small n) to purple (large n). Age groups with less than
10 cycles are not shown. (C) After age 35, mean euploidy rates decline with increasing maternal age, as shown by the close ﬁt between the
data points and the dashed regression line. The strong linear correlation (R2 ¼ 0.981) indicates that the equation for this line can be used to
accurately calculate (interpolate) average euploidy rates in women 35 to 45 years old. Adapted from Figures 2 and 3 in McCoy et al., 2015 (26).
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Fertility and Sterility®Data Analyses
Data were analyzed with R (version 3.1.2; www.r-projec-
t.org). We stratiﬁed data by maternal age and analyzed
distributions with quartiles. In addition, for each year of
age, we calculated the average number of euploid em-
bryos, proportion of euploid embryos, and PrE. The prob-
ability of not having any euploid embryos was deﬁned as
the number of cycles without any euploid embryos
divided by the total number of cycles. Subtracting thisVOL. 105 NO. 5 / MAY 2016probability from 1 gives the probability of retrieving at
least one euploid embryo (PrE). These outcome measures
were compared for day-3 and day-5 biopsies, and for em-
bryos from egg donors and nondonors. To quantitatively
describe the relationship between these measures and
advanced maternal age, we used linear and nonlinear
regression analyses, and we measured the strength of
the correlation between observed and predicted values
with the regression R2 values.1309
FIGURE 2
A B
Reported reasons for testing day-3 (A) and day-5 (B) biopsies with single-nucleotide polymorphism (SNP)–based preimplantation genetic screening
(PGS). The percentages of IVF cycles that submitted biopsies for eight different reasons are shown. It should be noted that reasons were not
reported in 51.1% of cycles that submitted day-3 biopsies and 23.0% of cycles that submitted day-5 biopsies. AMA ¼ advanced maternal age;
RPL ¼ recurrent pregnancy loss.
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A total of 46,439 embryo biopsies (6,325 cycles) from women
18 to 48 years old were submitted for PGS analysis. Overall,
more day-3 biopsies were submitted than day-5 biopsies
(28,052 vs. 18,387, respectively). For both day-3 and day-5
biopsies, the most common reasons for performing this test
were advanced maternal age, recurrent pregnancy loss, and
gender selection (Fig. 2). Because we aimed to determine the
effects of maternal age on embryo euploidy, we omitted
5,005 samples with unknown maternal age. In addition, we
excluded 3,723 samples that did not have sufﬁcient informa-
tion to determine embryo ploidy. The exclusion criteria were
low-conﬁdence copy-number calls [<80% conﬁdence (22)]
for ﬁve or more chromosomes or embryos called nullisomic
for all chromosomes. A total of 37,711 embryos from 5,821
cycles remained for analysis. The day-3 biopsies comprised
22,599 embryos from 2,652 cycles and day-5 biopsies
included 15,112 embryos from 3,169 cycles. There were
3,679 embryos (9.8%; 391 cycles) from egg donors and
34,032 embryos (90.2%; 5,430 cycles) from nondonors.Proportion of Euploid Embryos per Cycle
The median proportion of euploid embryos in each cycle re-
mained relatively steady at 35% in day-3 biopsies and
55% in day-5 biopsies in women 27 to 35 years old, and
then rapidly declined to 0 by age 44 (data not shown). These
results imply that the effect of maternal age on the proportion
of euploid embryos in each cycle is independent of biopsy
timing. Although the interquartile range (difference between
the 25th and 75th percentiles) of the euploid proportion in
day-5 embryos was higher than that in day-3 embryos for
nearly all maternal ages, this most likely reﬂects the smaller
number of day-5 embryos compared with day-3 embryos in
all age groups. For embryos from egg donors and nondonors
younger than 33 years old, the euploid proportion of day-3
and day-5 embryos in each cycle were similar.1310Number of Euploid Embryos per Cycle
For both day-3 and day-5 embryos, the average number
of euploid embryos per cycle declined from 4 euploid
embryos/cycle for women in their late 20s to <1 euploid em-
bryo/cycle after age 42 (Fig. 3A and 3B). After age 35, the
average number of euploid embryos decreased sharply, with
a strong inverse linear relationship with age in both day-3
and day-5 embryos (R2 ¼ 0.983 and 0.991, respectively;
Fig. 3C). The lack of a difference in these age-related declines
between day-3 and day-5 biopsies indicates that embryo
attrition during this period can be attributed to embryo aneu-
ploidy. For embryos from egg donors and nondonors under
33 years old, both day-3 and day-5 biopsies had similar
average numbers of euploid embryos. Speciﬁcally, egg donors
between 25 and 32 years old averaged 4.6 euploid embryos
/cycle on day 3 and 3.2 euploid embryos/cycle on day 5,
whereas nondonors in the same age range averaged 4.1
euploid embryos/cycle on day 3 and 3.4 euploid embryos/cy-
cle on day 5. These results suggest that the number of euploid
embryos per cycle does not depend on egg donor/nondonor
status.Probability of Retrieving at least One Euploid
Embryo in a Cohort
An important metric for women undergoing IVF is the likeli-
hood of having at least one euploid embryo in a fertility cycle
(i.e., PrE). Consistent with the observed effect of maternal age
on the number and proportion of euploid embryos, PrE was
high before age 35 years, and dropped quickly thereafter in
both day-3 and day-5 embryos (Fig. 4). Speciﬁcally, at age
35, at least one euploid embryo can be expected in approxi-
mately 85% of all cycles; this percentage drops to approxi-
mately 75% at age 40, and to approximately 45% by age
44. For women over 32, PrE is approximated by a Weibull
probability density function (R2 ¼ 0.986), which is an expo-
nential model of age-related failure rates (28, 29) that isVOL. 105 NO. 5 / MAY 2016
FIGURE 3
A
B
C
Distribution of the number of euploid embryos per IVF cycle from
women 25 to 45 years old. (A, B) The average number of euploid
embryos per cycle at (A) day 3 and (B) day 5 tends to decline with
increasing maternal age. Data points and whiskers show the mean
and one SD, respectively. In (A), the upper whiskers for ages 27
FIGURE 3 Continued
and 29 extend to 12.7 and 14.6 euploid embryos per cycle,
respectively. (C) After age 35, the average number of euploid
embryos per cycle decreases with increasing maternal age, as
shown by the strong correlation between the data points and the
dashed regression line. Colors represent the number of embryos in
each age group, as in Figure 1B. Age groups with less than 45
cycles are not shown.
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Fertility and Sterility®consistent with the acceleration in the age-related decrease in
PrE with increasing maternal age we observed here. For em-
bryos from egg donors and nondonors younger than 33 years
old, PrE was consistently high in both day-3 and day-5 bi-
opsies. Thus, PrE appears to be independent of biopsy timing
and not dependent on egg source.DISCUSSION
This is the largest known study of the effects of maternal age
on euploidy rates in preimplantation embryos analyzed with
24-chromosome PGS. Our results corroborate previously re-
ported euploidy rates as well as known relationships between
embryo euploidy and maternal age, biopsy timing, and egg
donor status (6, 12, 24, 30–33). Speciﬁcally, our ﬁnding that
only approximately one-third to one-half of all preimplanta-
tion embryos (day 3 and day 5) from women 18 to 48 years
old test as euploid is consistent with previous reports that
30% to 60% of preimplantation embryos screened with
comparative genomic hybridization or SNP arrays test as
aneuploid (7). Our data also conﬁrm that euploidy rates in
both day-3 and day-5 embryos remain roughly constant be-
tween 24 and 35 years of age, with a striking decrease there-
after. These trends agree well with a recent study of 15,169
day-5 embryos analyzed with SNP arrays that showed that
embryo aneuploidy rates and probabilities of there being no
euploid embryos in a cohort are lowest inwomen 26 to 30 years
old, and markedly increased in women over 35 (30).
Egg donors, who are required to be within the age range
associated with peak euploid proportion and PrE (30), can
help women of advanced maternal age overcome age-
related decreases in embryo euploidy and achieve a successful
pregnancy (9). Because the proportion of euploid embryos
from egg donors and nondonors under 33 was not statistically
signiﬁcantly different, the lower overall euploidy rate in em-
bryos from nondonors was consistent with a reduction in
euploid embryos as women age beyond 33 years. This ﬁnding
underscores the importance of considering maternal age
when predicting the likelihood of successful IVF outcomes,
particularly at advanced maternal ages. In addition, it sug-
gests that aneuploidy is not the primary cause of failed IVF
cycles in younger patients.
The ﬁnding that the number of euploid embryos per cycle
is essentially the same for day-3 and day-5 biopsies is in
agreement with a recent comparison of day-3 and day-5 em-
bryos using 24-chromosome array comparative genomic hy-
bridization analysis (34). Likewise, consistent with other
reports (6, 14, 24, 35, 36), we also observed that the
proportion of euploid embryos at day 5 tends to be higher1
FIGURE 4
Probability of retrieving at least one euploid embryo in a cohort of
embryos from women aged 21 to 45 years old. For both day-3 and
day-5 embryos, the probability of there being at least one euploid
embryo was relatively high in women <35 years old, but it
decreased rapidly in older women. After the age of 32, this decline
is modeled by an exponential curve (R2 ¼ 0.986; dotted black
curve). Note that this curve was ﬁt to data from both day-3 and
day-5 embryos.
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number of embryos at day 5 was less than that at day 3.
The precise counterbalance of these two metrics suggests
that the attrition of embryos from day 3 to day 5 is due
largely to aneuploidy; however, there are other possible
explanations, including attrition of euploid embryos
combined with trisomy rescue, and mosaicism.
The main strength and distinctive feature of our study is
the large number of preimplantation embryos that we
analyzed, which allowed us to characterize maternal age rela-
tionships in unprecedented detail and with accurate mathe-
matic models. These data should help fertility specialists
make more age-speciﬁc predictions of success for women
undergoing IVF with or without PGS.
Due to the retrospective nature of our study, our results
may have been limited by selection or information biases.
However, because of our large sample size, selection bias
resulting from samples that are not representative of the
population is likely to be minimal. In addition, information
bias due to misclassiﬁcation of embryo ploidy is not likely
to be signiﬁcant because the false-detection rate of SNP-
based PGS is as low as that of metaphase karyotyping
(<4%), the gold standard for chromosome analysis (22).
Furthermore, the consistency of our ﬁndings with known
maternal age relationships suggests that these common
limitations of retrospective studies were not signiﬁcant in
our study.
It should be noted that although PGS is expected to
increase implantation and pregnancy rates by selectively1312eliminating aneuploid embryos, there are many other factors
that may affect clinical outcomes. For example, chromosome
number is only one determinant of embryo health. Addition-
ally, technical aspects of IVF procedures such as the timing of
embryo biopsy, vitriﬁcation, and transfer can affect preg-
nancy outcomes. Finally, mosaicism in preimplantation em-
bryos, which is common at day 3 (21, 22), may lead to an
incorrect assessment of the potential of an embryo to
develop into a healthy euploid baby (37).
Nevertheless, because providing meaningful counseling
to patients undergoing IVF requires being able to compare
patients with peers of the same age and egg donor status,
we hope that our ﬁndings will help physicians, reproductive
specialists, and genetic counselors optimize IVF treatment.
Speciﬁcally, age- and donor-speciﬁc euploid proportions
and PrE values can be used to predict the likelihood of a suc-
cessful IVF outcome, help patients set realistic expectations
during treatment cycles, and facilitate the transition to subse-
quent cycles in the event of a failed cycle.
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